Synonym
BMS-561390; BMS561390; BMS561390; DPC-083; DPC 083; DPC083.
IUPAC/Chemical Name
(S,E)-6-chloro-4-(2-cyclopropylvinyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one
InChi Key
UXDWYQAXEGVSPS-GFUIURDCSA-N
InChi Code
InChI=1S/C14H12ClF3N2O/c15-9-3-4-11-10(7-9)13(14(16,17)18,20-12(21)19-11)6-5-8-1-2-8/h3-8H,1-2H2,(H2,19,20,21)/b6-5+/t13-/m0/s1
SMILES Code
O=C1NC2=C(C=C(Cl)C=C2)[C@](C(F)(F)F)(/C=C/C3CC3)N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
316.71
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Li S, Ma JA. Core-structure-inspired asymmetric addition reactions: enantioselective synthesis of dihydrobenzoxazinone- and dihydroquinazolinone-based anti-HIV agents. Chem Soc Rev. 2015 Nov 7;44(21):7439-48. doi: 10.1039/c5cs00342c. Review. PubMed PMID: 26177889.
2: Bindra DS, Desikan S. Impact of micromeritic properties of an active pharmaceutical ingredient on its compaction behavior. Pharm Dev Technol. 2015 Mar;20(2):129-38. doi: 10.3109/10837450.2013.852569. PubMed PMID: 24219704.
3: Yuan HN, Li S, Nie J, Zheng Y, Ma JA. Highly enantioselective decarboxylative Mannich reaction of malonic acid half oxyesters with cyclic trifluoromethyl ketimines: synthesis of β-amino esters and anti-HIV drug DPC 083. Chemistry. 2013 Nov 18;19(47):15856-60. doi: 10.1002/chem.201303307. PubMed PMID: 24150893.
4: Yuan HN, Wang S, Nie J, Meng W, Yao Q, Ma JA. Hydrogen-bond-directed enantioselective decarboxylative Mannich reaction of β-ketoacids with ketimines: application to the synthesis of anti-HIV drug DPC 083. Angew Chem Int Ed Engl. 2013 Apr 2;52(14):3869-73. doi: 10.1002/anie.201210361. PubMed PMID: 23460261.
5: Zhang FG, Zhu XY, Li S, Nie J, Ma JA. Highly enantioselective organocatalytic Strecker reaction of cyclic N-acyl trifluoromethylketimines: synthesis of anti-HIV drug DPC 083. Chem Commun (Camb). 2012 Dec 7;48(94):11552-4. doi: 10.1039/c2cc36307k. PubMed PMID: 23090241.
6: Xie H, Zhang Y, Zhang S, Chen X, Wang W. Bifunctional Cinchona alkaloid thiourea catalyzed highly efficient, enantioselective aza-Henry reaction of cyclic trifluoromethyl ketimines: synthesis of anti-HIV drug DPC 083. Angew Chem Int Ed Engl. 2011 Dec 2;50(49):11773-6. doi: 10.1002/anie.201105970. PubMed PMID: 21989976.
7: Zeng ZS, He QQ, Liang YH, Feng XQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. Bioorg Med Chem. 2010 Jul 15;18(14):5039-47. doi: 10.1016/j.bmc.2010.05.081. PubMed PMID: 20598556.
8: De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers. 2004 Jan;1(1):44-64. Review. PubMed PMID: 17191775.
9: Duchowicz PR, Fernández M, Caballero J, Castro EA, Fernández FM. QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem. 2006 Sep 1;14(17):5876-89. PubMed PMID: 16766190.
10: Tarby CM. Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. Curr Top Med Chem. 2004;4(10):1045-57. Review. PubMed PMID: 15193138.
11: Gulick RM. New antiretroviral drugs. Clin Microbiol Infect. 2003 Mar;9(3):186-93. Review. PubMed PMID: 12667250.
12: Magnus NA, Confalone PN, Storace L, Patel M, Wood CC, Davis WP, Parsons RL Jr. General scope of 1,4-diastereoselective additions to a 2(3H)-quinazolinone: practical preparation of HIV therapeutics. J Org Chem. 2003 Feb 7;68(3):754-61. PubMed PMID: 12558396.
13: De Clercq E. Highlights in the development of new antiviral agents. Mini Rev Med Chem. 2002 Apr;2(2):163-75. Review. PubMed PMID: 12370077.
14: De Clercq E. New anti-HIV agents and targets. Med Res Rev. 2002 Nov;22(6):531-65. Review. PubMed PMID: 12369088.
15: Susman E. NNRTI without the rash. AIDS. 2002 Aug 16;16(12):N8. PubMed PMID: 12214592.
16: Gallant JE. New antiretroviral agents. Hopkins HIV Rep. 2001 Mar;13(2):2, 16. PubMed PMID: 12184261.
17: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 May;24(4):217-48. Review. PubMed PMID: 12092009.
18: De Clercq E. New developments in anti-HIV chemotherapy. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):258-75. Review. PubMed PMID: 12084468.
19: Lim ML. DPC-083. DuPont Pharmaceuticals. Curr Opin Investig Drugs. 2001 Sep;2(9):1209-12. Review. PubMed PMID: 11717806.
20: Arastéh K, Müller M. [New antiretroviral drugs. Improved pharmacokinetics and simpler dose schedules]. MMW Fortschr Med. 2001 Apr 2;143 Suppl 1:14-7. Review. German. PubMed PMID: 11373768.
